Analysts lose confidence in Biogen Alzheimer's approval
There have been so many controversies surrounding Biogen's drug candidate for Alzheimer's disease, aducanumab, that analysts now see its approval chances as vanishingly low.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
With the deadline for the FDA (US Food and Drug Administration)'s decision on Biogen's drug aducanumab fast approaching, analysts at RBC Capital Markets are less and less convinced that the result will be in Biogen's favor, writes Fiercepharma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly skyrockets following positive Alzheimer's data
For subscribers
